VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

WCLC Sept 2021 | Future perspectives in lung cancer

Melissa Johnson, MD, Sarah Cannon Research Institute, Nashville, TN, shares her perspectives on key ongoing research topics in lung cancer. To begin with, it is important to accelerate the development of biomarkers that will help identify the most appropriate drug for newly diagnosed patients with non-small cell lung cancer (NSCLC), as well as biomarkers of drug resistance for patients who progress on anti-PD-1 therapy. Moreover, novel promising immunotherapies such as antibody-drug conjugates and bispecific antibodies are currently being examined for NSCLC and small cell lung cancer (SCLC). Dr Johnson also comments on the recent approval of sotorasib for patients with KRAS G12C-mutated NSCLC and mentions ongoing research focusing on improving the efficacy of this KRAS G12C inhibitor, as well as research on new targeted therapies and immunotherapies for patients with NSCLC with other KRAS mutations. This interview took place at the World Conference on Lung Cancer (WCLC) 2021.

Disclosures

Research funding (all payments made to institution): AbbVie,  Acerta, Adaptimmune, Amgen, Apexigen, Arcus Biosciences, Array BioPharma, Artios Pharma, AstraZeneca, Atreca, BeiGene, BerGenBio, BioAtla, Boehringer Ingelheim, Calithera Biosciences, Checkpoint Therapeutics, Corvus Pharmaceuticals, Curis, CytomX, Daiichi Sankyo, Dracen Pharmaceuticals, Dynavax, Lilly, Elicio Therapeutics, EMD Serono, Erasca, Genentech/Roche, Genmab, Genocea Biosciences, GlaxoSmithKline, Gritstone Oncology, Guardant Health, Harpoon, Helsinn Healthcare SA, Hengrui Therapeutics, Hutchison MediPharma, IDEAYA Biosciences, IGM Biosciences, Immunocore, Incyte, Janssen, Jounce Therapeutics, Kadmon Pharmaceuticals, Loxo Oncology, Lycera, Memorial , Sloan-Kettering, Merck, Mirati Therapeutics, NeoImmune Tech, Neovia Oncology, Novartis, Numab Therapeutics, OncoMed Pharmaceuticals, Pfizer, PMV Pharmaceuticals, RasCal Therapeutics, Regeneron Pharmaceuticals, Relay Therapeutics, Revolution Medicines, Ribon Therapeutics, Rubius Therapeutics, Sanofi, Seven and Eight Biopharmaceuticals / Birdie Biopharmaceuticals, Shattuck Labs, Silicon Therapeutics, Stem CentRx, Syndax Pharmaceuticals, Takeda Pharmaceuticals, Tarveda, TCR2 Therapeutics, Tempest Therapeutics, Tizona Therapeutics, TMUNITY, Therapeutics, Turning Point Therapeutics, University of Michigan, Vyriad, WindMIL, Y-mAbs Therapeutics
Consulting/advisory role (all payments made to institution): AbbVie, Achilles Therapeutics, Amgen, AstraZeneca, Axelia Oncology, Atreca, Black Diamond, Boehringer Ingelheim, Bristol-Myers Squibb, Calithera Biosciences, Checkpoint Therapeutics, CytomX Therapeutics, Daiichi Sankyo, EcoR1, Editas Medicine, Eisai, EMD Serono, G1 Therapeutics, Genentech / Roche, Genmab, GlaxoSmithKline, Gritstone Oncology, Guardant Health, Ideaya Biosciences, iTeos, Incyte, Janssen, Lilly, Loxo Oncology, Merck, Mirati Therapeutics, Novartis, Oncorus, Pfizer, Regeneron Pharmaceuticals, Ribon Therapeutics, Sanofi-Aventis, Turning , Point Therapeutics, WindMIL.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter